Lyell Immunopharma
LYEL
trading on NASDAQ
since 2021
0
(Δ 0%)
+$0.00 since open
Lyell Immunopharma is a biotechnology company focused on developing engineered T cell-based therapies to treat cancer by targeting specific antigens expressed on cancer cells.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $13.62 | $13.63 | $9.67 | $5.95M | 786.67K |
| eps | p/e | p/s |
operating margin |
profit margin |
yield |
| -$0.18 | n/a | n/a | -819528.57% | -745642.86% | 0% |